ArticleBMC women's health2026
Effect of coriolus versicolor-based vaginal gel on clearance of human papillomavirus and cervical dysplasia - a scoping review.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer, primarily caused by sexually transmitted high-risk Human Papillomavirus (HPV) infections, remains a major global health challenge. Despite significant advances in HPV vaccination and cervical cancer screening strategies, effective and non-invasive treatment options for HPV infections and cervical dysplasia. are still lacking. Current management strategies of cervical dysplasia vary from the “wait and see” strategy to surgical interventions. This scoping review aimed to map the existing evidence on the efficacy and safety of Coriolus Versicolor (CV)-based vaginal gel as a novel and effective non-invasive treatment of HPV infection and mild cervical dysplasia.
methodsA comprehensive scoping review was performed using systematic searches in PubMed, Embase, EBSCOhost, Ovid, CNKI and SciELOdatabases. The literature search covered publications up to August 2025. Two reviewers independently screened possible studies, following the PRISMA guidelines for scoping reviews. Only human experimental randomized controlled trial (RCT) and observational cohort studies published in English, Norwegian, Swedish or Danish were considered.
resultsA total of 127 articles were screened, and five studies met the inclusion criteria: one RCT (n = 91), one sub-analysis of this RCT (n = 41), and three cohort studies (n = 183, 192, 21). Treatment with CV-based vaginal gel was associated with improved HPV clearance and regression of cervical dysplastic lesions, with regression rates of 76.1–84.9% in treated women compared 40.8–64.5% in untreated controls. Positive effects were also observed in women with hrHPV and in postmenopausal women. No serious adverse events were reported.
conclusionThis scoping review suggests that CV-based vaginal gel shows promising but preliminary efficacy and safety in promoting regression of cervical dysplastic lesions and HPV clearance. Larger, long-term multinational RCT studies with standardized outcomes definitions are needed to confirm these preliminary findings and to establish the therapeutic role of the CVbased vaginal gel in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.